Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum

ClinicalTrials.gov ID: NCT00003160

Public ClinicalTrials.gov record NCT00003160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer

Study identification

NCT ID
NCT00003160
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Theradex
Industry
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 1997
Primary completion
Not listed
Completion
Not listed
Last update posted
Apr 19, 2011

Started 1997

United States locations

U.S. sites
18
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
Oncology Center at Providence Park Mobile Alabama 36608
Hematology Associates, Ltd. Phoenix Arizona 85013
Highlands Oncology Group, P.A. Fayetteville Arkansas 72703
Cancer Center of Santa Barbara Santa Barbara California 93105
Good Samaritan Medical Center West Palm Beach Florida 33401
Decatur Memorial Hospital Cancer Care Institute Decatur Illinois 62526
Creighton University Cancer Center Omaha Nebraska 68131-2197
Jersey Shore Cancer Center Neptune City New Jersey 07753
Women's Health Center at Albany Medical Center Albany New York 12209
Carolinas Medical Center Charlotte North Carolina 28232-2861
Akron General Medical Center Akron Ohio 44302
Oncology/Hematology Care, Inc. Cincinnati Ohio 45219
Cleveland Clinic Cancer Center Cleveland Ohio 44195
Women's Cancer Center of Central PA, P.C. Harrisburg Pennsylvania 17105-8700
Women and Infants Hospital of Rhode Island Providence Rhode Island 02905
Brookview Research, Inc. Nashville Tennessee 37203
Harrington Cancer Center Amarillo Texas 79106
Rockwood Clinic P.S. Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2011 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003160 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →